Hantong Medical Secures $14M Pre-A Funding to Accelerate Ultrasound RDN Commercialization

Shanghai-based Hantong Medical (汉通医疗) has successfully closed a Pre-A funding round of 100 million RMB ($14 million), with participation from Fortune Capital (达晨财智), Jifeng Ventures (济峰资本), and Pudong Angel Venture Fund (浦东天使创业基金). The newly secured funds will be used to advance the clinical development and commercialization of its ultrasound renal denervation (RDN) technology, while also driving the R&D of innovative interventional ultrasound products.

Founded in 2022, Hantong Medical is an innovation-driven platform company specializing in interventional ultrasound solutions for vascular-related conditions. The completion of this oversubscribed funding round reflects strong investor confidence in the company’s leadership in RDN industrialization and long-term growth potential.

“Our second-generation ultrasound RDN product has rapidly progressed into the clinical stage, with dozens of successful cases demonstrating outstanding safety and efficacy,” said Dr. Wanjin Zhao (赵万金), Founder and CEO of Hantong Medical. “This financing will accelerate the development and clinical trials of our pipeline products. Moving forward, we will remain committed to integrating cutting-edge ultrasound technology with clinical needs, delivering differentiated and breakthrough interventional solutions that address critical healthcare challenges and improve patient outcomes.”